利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.031 秒)

    C-Met receptor regulation by angiotensin IV (AT4 ) receptor ligands
    1.
    发明授权
    C-Met receptor regulation by angiotensin IV (AT4 ) receptor ligands 有权
    血管紧张素IV（AT4）受体配体的C-Met受体调节

    公开(公告)号：US07910555B2

    公开(公告)日：2011-03-22

    申请号：US11774517

    申请日：2007-07-06

    申请人： Joseph W. Harding ,  John W. Wright ,  Patrick D. Elias ,  Brent J. Yamamoto

    发明人： Joseph W. Harding ,  John W. Wright ,  Patrick D. Elias ,  Brent J. Yamamoto

    IPC分类号： A61K38/08

    CPC分类号： A61K38/085 ,  A61K38/1833 ,  C12N9/0008 ,  C12N9/88 ,  C12N9/93

    摘要： The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis cancer metastasis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor.

    摘要翻译： 肝细胞生长因子（HGF）信号介导的细胞表面c-Met受体已被鉴定为包括HGF调节的细胞运动，血管发生癌转移的过程中的血管紧张素-IV受体（AT（4）R） 和别的。 公开了使用它们来诊断，预防和/或治疗与c-Met失调相关的病症的血管紧张素样因子组合物和方法，包括通过施用特异性结合的血管紧张素样因子来改变肝细胞生长因子活性或c-Met受体活性 到细胞表面c-Met受体。

    C-MET RECEPTOR REGULATION BY ANGIOTENSIN IV (AT4) RECEPTOR LIGANDS
    2.
    发明申请
    C-MET RECEPTOR REGULATION BY ANGIOTENSIN IV (AT4) RECEPTOR LIGANDS 有权
    C-MET受体由血管紧张素II（AT4）受体配体调节

    公开(公告)号：US20130023475A1

    公开(公告)日：2013-01-24

    申请号：US13547601

    申请日：2012-07-12

    申请人： Joseph W. Harding ,  John W. Wright ,  Patrick D. Elias ,  Brent J. Yamamoto ,  Leen H. Kawas

    发明人： Joseph W. Harding ,  John W. Wright ,  Patrick D. Elias ,  Brent J. Yamamoto ,  Leen H. Kawas

    IPC分类号： A61K38/08 ,  A61K38/10 ,  A61P25/16 ,  A61P25/00

    CPC分类号： A61K38/085 ,  A61K38/1833 ,  C07K5/06034 ,  C07K5/06078 ,  C07K5/06086 ,  C07K5/06095 ,  C07K5/06113 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/0815 ,  C07K5/0817 ,  C07K5/0819 ,  C07K5/101 ,  C07K5/1016 ,  C07K5/1019 ,  C07K5/1021 ,  C07K14/705 ,  G01N33/502 ,  G01N33/5023 ,  G01N33/6893 ,  G01N2800/044

    摘要： The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including cancer, obesity and conditions associated with obesity, and other disorders, for example, by altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor. In addition, members of this group of molecules may useful for treating or preventing the development of neurodegenerative diseases like general dementia, Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis and initiating recovery from traumatic brain injury and spinal cord trauma. These peptides and peptidomimetics may be therapeutically useful whenever increased neurotrophic activity would be clinically advantageous.

    摘要翻译： 肝细胞生长因子（HGF）信号介导的细胞表面c-Met受体已被鉴定为血管紧张素-IV受体（AT（4）R），其包括HGF调节的细胞运动，血管生成，癌症 转移，脂肪形成等。 公开了血管紧张素样因子组合物和使用它们来诊断，预防和/或治疗与c-Met失调相关的病症的方法，包括癌症，肥胖症和与肥胖相关的病症以及其他病症，例如通过改变肝细胞生长因子 活性或c-Met受体活性，通过施用特异性结合细胞表面c-Met受体的血管紧张素样因子。 此外，该组分子的成员可用于治疗或预防神经变性疾病如一般性痴呆，阿尔茨海默氏病，帕金森病和肌萎缩性侧索硬化的发展，并且从创伤性脑损伤和脊髓创伤引发恢复。 每当增加的神经营养活性在临床上是有利的时候，这些肽和肽模拟物可以是治疗上有用的。